Crystal structure of human dihydrofolate reductase complexed with folate
- PMID: 3383852
- DOI: 10.1111/j.1432-1033.1988.tb14108.x
Crystal structure of human dihydrofolate reductase complexed with folate
Abstract
The crystal structure of recombinant human dihydrofolate reductase with folate bound in the active site has been determined and the structural model refined at 0.2-nm resolution. Preliminary studies of the binding of the inhibitors methotrexate and trimethoprim to the human apoenzyme have been performed at 0.35-nm resolution. The conformations of the chemically very similar ligands folate and methotrexate, one a substrate the other a potent inhibitor, differ substantially in that their pteridine rings are in inverse orientations relative to their p-aminobenzoyl-L-glutamate moieties. Methotrexate binding is similar to that previously observed in two bacterial enzymes but is quite different from that observed in the enzyme from a mouse lymphoma cell line [Stammers et al. (1987) FEBS Lett. 218, 178-184]. The geometry of the polypeptide chain around the folate binding site in the human enzyme is not consistent with conclusions previously drawn with regard to the species selectivity of the inhibitor trimethoprim [Matthews et al. (1985) J. Biol. Chem. 260, 392-399].
Similar articles
-
Isomorphous crystal structures of Escherichia coli dihydrofolate reductase complexed with folate, 5-deazafolate, and 5,10-dideazatetrahydrofolate: mechanistic implications.Biochemistry. 1995 Feb 28;34(8):2710-23. doi: 10.1021/bi00008a039. Biochemistry. 1995. PMID: 7873554
-
Crystal structures of Escherichia coli dihydrofolate reductase complexed with 5-formyltetrahydrofolate (folinic acid) in two space groups: evidence for enolization of pteridine O4.Biochemistry. 1996 Jun 4;35(22):7012-20. doi: 10.1021/bi960028g. Biochemistry. 1996. PMID: 8679526
-
Folic acid: crystal structure and implications for enzyme binding.Science. 1980 Oct 17;210(4467):334-6. doi: 10.1126/science.7423195. Science. 1980. PMID: 7423195
-
Conformational flexibility and protein specificity.Ciba Found Symp. 1991;158:169-82; discussion 182-6, 204-12. Ciba Found Symp. 1991. PMID: 1935420 Review.
-
Dihydrofolate reductase as a therapeutic target.FASEB J. 1990 May;4(8):2441-52. doi: 10.1096/fasebj.4.8.2185970. FASEB J. 1990. PMID: 2185970 Review.
Cited by
-
Single agents with designed combination chemotherapy potential: synthesis and evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents.J Med Chem. 2010 Feb 25;53(4):1563-78. doi: 10.1021/jm9011142. J Med Chem. 2010. PMID: 20092323 Free PMC article.
-
Isolation and characterization of a dihydrofolate reductase gene mutation in methotrexate-resistant Drosophila cells.Gene Expr. 1996;6(4):231-9. Gene Expr. 1996. PMID: 9196078 Free PMC article.
-
Native-like structure of a protein-folding intermediate bound to the chaperonin GroEL.Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1080-5. doi: 10.1073/pnas.94.4.1080. Proc Natl Acad Sci U S A. 1997. PMID: 9037009 Free PMC article.
-
Distal Regions Regulate Dihydrofolate Reductase-Ligand Interactions.Methods Mol Biol. 2021;2253:185-219. doi: 10.1007/978-1-0716-1154-8_12. Methods Mol Biol. 2021. PMID: 33315225 Review.
-
Cytosolic localization and in vitro assembly of human de novo thymidylate synthesis complex.FEBS J. 2022 Mar;289(6):1625-1649. doi: 10.1111/febs.16248. Epub 2021 Nov 12. FEBS J. 2022. PMID: 34694685 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
